Tiziana Life Sciences Ltd — Investor Relations & Filings
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| REPORT OF FOREIGN PRIVATE ISSUER | 2024-01-05 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2023-12-29 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2023-12-19 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2023-12-04 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2023-12-01 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2023-11-30 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
1 filing
| |||||
| 13075363 | REPORT OF FOREIGN PRIVATE ISSUER | 2024-01-05 | English | ||
|
2023
14 filings
| |||||
| 13075364 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-12-29 | English | ||
| 13075365 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-12-19 | English | ||
| 13075366 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-12-04 | English | ||
| 13075367 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-12-01 | English | ||
| 13075368 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-11-30 | English | ||
| 13075369 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-11-01 | English | ||
| 13075370 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-10-18 | English | ||
| 13075371 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-10-16 | English | ||
| 13075372 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-10-13 | English | ||
| 13075373 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-10-11 | English | ||
| 13075374 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-09-26 | English | ||
| 13075376 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-09-08 | English | ||
| 13075375 | REPORT OF FOREIGN PRIVATE ISSUER | 2023-09-06 | English | ||
| 13075377 | PROSPECTUS SUPPLEMENT | 2023-09-01 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Tiziana Life Sciences Ltd, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Tiziana Life Sciences Ltd via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33662/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33662 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33662 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33662 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33662}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Tiziana Life Sciences Ltd (id: 33662)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.